24/7 Market News Snapshot 24 July, 2025 – Sensus Healthcare, Inc (NASDAQ:SRTS)

July 24, 2025

DENVER, Colo., 24 July, 2025 (www.247marketnews.com) – (NASDAQ:SRTS) are discussed in this article.
Sensus Healthcare, Inc. (SRTS) has experienced a significant surge in its stock performance following the announcement of its new Medical Device Single Audit Program (MDSAP) certification. The company, known for its advanced non-invasive medical treatments for skin conditions, opened at $4.80 today and rapidly climbed over 20% to reach $5.68, highlighting robust investor confidence. With a volume of 504.98K shares traded, the market is clearly responding favorably to Sensus Healthcare’s strategic advancements.

The MDSAP certification, obtained for the company’s entire portfolio of superficial radiation therapy (SRT) systems—including the SRT-100®, SRT-100+™, and SRT-100 Vision™—is a transformative milestone that streamlines regulatory compliance across international markets. This certification enables Sensus to meet the Quality Management System (QMS) requirements of multiple regulatory bodies with a single audit, significantly enhancing its global market access.

Michael Sardano, President and General Counsel of Sensus Healthcare, remarked on the importance of this certification in bolstering the company’s global presence. It not only facilitates more efficient compliance with QMS standards but also accelerates the roll-out of innovative treatment solutions in high-potential regions. The reduction of audit-related burdens allows for quicker product registration, positioning the company to enhance its distribution capabilities and engage more effectively with hospitals and specialty clinics.

Benson Suen, Vice President of International Sales, underscored the competitive advantage brought by the MDSAP certification, aiming to minimize regulatory barriers and enhance international adoption of SRT systems. As Sensus Healthcare continues to prioritize quality and innovation in the field of radiation oncology, it remains poised to redefine treatment options in dermatological care, driving both market growth and improved patient outcomes.

Related news for (SRTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.